Fatigue News and Research

RSS

α1-adrenoceptor blockade improves nocturia and sleep quality

Treatment with an α1-adrenoceptor antagonist drug is associated with significant improvements in nocturia, sleep quality and lower urinary tract symptoms in women with voiding symptoms, study findings show.

21 Jul 2014

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to U.S. healthcare providers. This is the first shipment of GSK’s U.S. flu vaccine supply for the flu season, following licensing and lot-release approval from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research.

17 Jul 2014

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura).

16 Jul 2014

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA.

16 Jul 2014

CGP partners with Leader Prospects to serve employees of Indian companies

Chestnut Global Partners (www.chestnutglobalpartners.org), a provider of culturally-aware employee assistance and wellness programs to companies worldwide, today announced that it has partnered with Leader Prospects, an HR and work/life consulting company based in India, to form CGP India (CGPI).

15 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014

Counselling and guidance techniques may not be appropriate for many African countries

Counselling and guidance techniques developed in the Western world may not be appropriate for many African countries, where cultural influences, government policies and the availability of resources can have significant implications for service delivery.

11 Jul 2014

Letrozole drug results in higher birth rates in women with PCOS

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College of Medicine researchers.

10 Jul 2014

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok.

9 Jul 2014

Doctors offer new minimally invasive system to treat patients with narrowed, failing aortic heart

Doctors at the Orlando Health Heart Institute are offering a new minimally invasive system to treat patients with narrowed, failing aortic heart valves who are considered to be at high risk to undergo surgery. Orlando Health is the only hospital in Orlando currently offering the Medtronic CoreValve® System.

From Medtronic 8 Jul 2014

Hypertension does not respond to therapy due to inadequate diagnosis

High blood pressure—also known as hypertension—is widespread, but treatment often fails. One in five people with hypertension does not respond to therapy. This is frequently due to inadequate diagnosis, as Franz Weber and Manfred Anlauf point out in the current issue of Deutsches Ärzteblatt International.

8 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

7 Jul 2014

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program.

3 Jul 2014

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.

3 Jul 2014

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI BioPharma Corp. announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis.

From Baxter International Inc. 1 Jul 2014

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

30 Jun 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL).

28 Jun 2014

Fatigue News and Research

α1-adrenoceptor blockade improves nocturia and sleep quality

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Hydroxychloroquine treatment not effective for primary Sjögren syndrome

CGP partners with Leader Prospects to serve employees of Indian companies

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Counselling and guidance techniques may not be appropriate for many African countries

Letrozole drug results in higher birth rates in women with PCOS

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Doctors offer new minimally invasive system to treat patients with narrowed, failing aortic heart

Hypertension does not respond to therapy due to inadequate diagnosis

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News